Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

Increased flux of glucose through the hexosamine biosynthetic pathway (HSP) is believed to mediate hyperglycemia-induced insulin resistance in diabetes. The end product of the HSP, UDPβ- N -acetylglucosamine (GlcNAc), is a donor sugar nucleotide for complex glycosylation in the secretory pathway and for O-linked GlcNAc (O-GlcNAc) addition to nucleocytoplasmic proteins. Cycling of the O-GlcNAc posttranslational modification was blocked by pharmacological inhibition of O-GlcNAcase, the enzyme that catalyzes O-GlcNAc removal from proteins, with O -(2-acetamido-2-deoxy- d -glucopyranosylidene)amino- N -phenylcarbamate (PUGNAc). PUGNAc treatment increased levels of O-GlcNAc and caused insulin resistance in 3T3-L1 adipocytes. Insulin resistance induced through the HSP by glucosamine and chronic insulin treatment correlated with increased O-GlcNAc levels on nucleocytoplasmic proteins. Whereas insulin receptor autophosphorylation and insulin receptor substrate 2 tyrosine phosphorylation were not affected by PUGNAc inhibition of O-GlcNAcase, downstream phosphorylation of Akt at Thr-308 and glycogen synthase kinase 3β at Ser-9 was inhibited. PUGNAc-induced insulin resistance was associated with increased O-GlcNAc modification of several proteins including insulin receptor substrate 1 and β-catenin, two important effectors of insulin signaling. These results suggest that elevation of O-GlcNAc levels attenuate insulin signaling and contribute to the mechanism by which increased flux through the HSP leads to insulin resistance in adipocytes.

Bibliography

Vosseller, K., Wells, L., Lane, M. D., & Hart, G. W. (2002). Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proceedings of the National Academy of Sciences, 99(8), 5313–5318.

Authors 4
  1. Keith Vosseller (first)
  2. Lance Wells (additional)
  3. M. Daniel Lane (additional)
  4. Gerald W. Hart (additional)
References 62 Referenced 401
  1. H Yki-Jarvinen, V Koivisto Ann Clin Res 16, 74–83 (1984). / Ann Clin Res by Yki-Jarvinen H (1984)
  2. 10.2337/diacare.15.3.418
  3. Y T Kruszynska, J M Olefsky J Invest Med 44, 413–428 (1996). / J Invest Med by Kruszynska Y T (1996)
  4. 10.1172/JCI112981
  5. S R Hager, A L Jochen, R K Kalkhoff Am J Physiol 260, E353–E362 (1991). / Am J Physiol by Hager S R (1991)
  6. 10.1038/414813a
  7. 10.2337/diacare.13.6.610
  8. 10.1016/S0021-9258(19)67706-9
  9. 10.1172/JCI118876
  10. 10.2337/diab.45.8.1003
  11. 10.2337/diab.42.9.1333
  12. 10.1172/JCI118013
  13. 10.1007/BF00400719
  14. 10.1172/JCI118349
  15. 10.1172/JCI119390
  16. 10.1146/annurev.biochem.66.1.315
  17. 10.1096/fj.01-0094rev
  18. 10.1074/jbc.272.14.9308
  19. 10.1074/jbc.272.14.9316
  20. 10.1074/jbc.274.45.32015
  21. 10.1074/jbc.275.15.10983
  22. 10.1016/S0026-0495(98)90058-0
  23. 10.1007/978-1-4615-1885-3_10
  24. 10.1006/bbrc.1997.6110
  25. 10.1016/S0300-9084(01)01295-0
  26. 10.1126/science.1058714
  27. 10.1074/jbc.270.32.18961
  28. 10.1016/S0021-9258(18)82216-5
  29. 10.1074/jbc.271.46.28741
  30. 10.1021/bi0027480
  31. 10.1074/jbc.R000010200
  32. 10.1016/S0304-4165(99)00105-1
  33. 10.1210/endo-128-5-2415
  34. 10.1016/S0021-9258(17)32170-1
  35. 10.1074/jbc.M010420200
  36. 10.1074/jbc.M109656200
  37. 10.1074/jbc.273.6.3611
  38. 10.1074/jbc.272.12.7759
  39. 10.1073/pnas.87.1.251
  40. 10.1016/S0021-9258(19)85559-X
  41. 10.1006/abio.2001.5132
  42. 10.1016/S0021-9258(18)89409-1
  43. Y Kido, J Nakae, D Accili J Clin Endocrinol Metab 86, 972–979 (2001). / J Clin Endocrinol Metab by Kido Y (2001)
  44. 10.1074/jbc.271.49.31372
  45. 10.1128/MCB.19.6.4008
  46. 10.1128/MCB.18.12.6971
  47. 10.1016/S0960-9822(06)00122-9
  48. 10.1042/bj2940625
  49. 10.1038/378785a0
  50. 10.1074/jbc.273.21.13150
  51. 10.1126/science.254.5029.274
  52. M F White Recent Prog Horm Res 53, 119–138 (1998). / Recent Prog Horm Res by White M F (1998)
  53. 10.1046/j.1365-2443.1998.00198.x
  54. 10.1074/jbc.273.18.10823
  55. 10.2337/diabetes.49.6.981
  56. 10.1073/pnas.97.22.12222
  57. 10.2337/diabetes.48.8.1562
  58. 10.1074/jbc.M108594200
  59. E Heart, W S Choi, C K Sung Am J Physiol 278, E103–E112 (2000). / Am J Physiol by Heart E (2000)
  60. 10.1038/sj.onc.1204064
  61. 10.1093/emboj/20.21.5999
  62. 10.1128/MCB.21.5.1633-1646.2001
Dates
Type When
Created 23 years, 1 month ago (July 26, 2002, 10:45 a.m.)
Deposited 3 years, 4 months ago (April 12, 2022, 5:10 p.m.)
Indexed 1 week ago (Aug. 20, 2025, 8:33 a.m.)
Issued 23 years, 4 months ago (April 16, 2002)
Published 23 years, 4 months ago (April 16, 2002)
Published Online 23 years, 4 months ago (April 16, 2002)
Published Print 23 years, 4 months ago (April 16, 2002)
Funders 0

None

@article{Vosseller_2002, title={Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes}, volume={99}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.072072399}, DOI={10.1073/pnas.072072399}, number={8}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Vosseller, Keith and Wells, Lance and Lane, M. Daniel and Hart, Gerald W.}, year={2002}, month=apr, pages={5313–5318} }